I looked at the bang for the buck previously, after the first two rounds of financing, and it looked to me as though the investments resulted in a 3X effect.
"How did the first two rounds of financing affect us? I don't recall exactly what our Market Cap was before adding the almost $150M we raised from the PIPE and the public offerings, but I'm guessing it was about $450M. If share price didn't change, even from these dilutive offerings, we should now be at about $600M in market cap. But we're not. We are at $900M."
The controlled equity offering is for $100M, and we currently see our market cap now is also $100M higher, at $1B. If this cap raise has the same effect as the first two, we should be at $900M + ($100M x 3) = $1.2B. I think we will far surpass that, since we are expecting FDA approval. I'm hoping that news will allow me to fill my open sell order at the $6B market cap level (remember NVAX spiked to an $11B Market Cap, since they were so early with positive results. And they are still holding an $8.8B market cap).
My dream would be to see Humanigen acquire a developing manufacturer, or to develop their own internal capacity, or to merge with an established manufacturer that already has a revenue stream. Humanigen executives have long expressed concern about manufacturing capacity utilization. With the manufacturing profit margins, which likely reflect high demand, and with Covid being the tip of the demand iceberg, to be followed by continued demand for other indications, such as cancer, GvHD, etc., the manufacturing component may be even more profitable than the commercial component. And it would eliminate what could pose a risk of short supply.
News 
Market Data 
Discover 
